Dr. Ragisha Gopalakrishnan, MD ...

Dr. Ragisha Gopalakrishnan

Claim this profile

Mount Sinai Medical Center

Studies Breast Cancer
Studies Colorectal Cancer
7 reported clinical trials
15 drugs studied

Area of expertise

1

Breast Cancer

Ragisha Gopalakrishnan has run 4 trials for Breast Cancer. Some of their research focus areas include:

HER2 positive
PR positive
ER positive
2

Colorectal Cancer

Ragisha Gopalakrishnan has run 1 trial for Colorectal Cancer. Some of their research focus areas include:

Stage IV
KRAS negative

Affiliated Hospitals

Image of trial facility.

Mount Sinai Medical Center

Image of trial facility.

Mount Sinai Comprehensive Cancer Center At Aventura

Clinical Trials Ragisha Gopalakrishnan is currently running

Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Recruiting

2 awards

Phase 3

40 criteria

Image of trial facility.

Alpelisib + Tucatinib

for Breast Cancer

This trial tests a combination of two drugs, tucatinib and alpelisib, in patients with a specific type of advanced breast cancer. These patients have a genetic mutation and a type of cancer that may not respond well to standard treatments. The drugs work by blocking signals that help cancer cells grow. Alpelisib is approved for treating certain types of advanced breast cancer.

Recruiting

1 award

Phase 1 & 2

11 criteria

More about Ragisha Gopalakrishnan

Clinical Trial Related

2 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Ragisha Gopalakrishnan has experience with

  • AlloStim
  • Radiation Therapy
  • Olaparib
  • Alpelisib
  • Tucatinib
  • Decision Aid

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Ragisha Gopalakrishnan specialize in?

Is Ragisha Gopalakrishnan currently recruiting for clinical trials?

Are there any treatments that Ragisha Gopalakrishnan has studied deeply?

What is the best way to schedule an appointment with Ragisha Gopalakrishnan?

What is the office address of Ragisha Gopalakrishnan?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security